|  |  |  |  |
| --- | --- | --- | --- |
|  | Residual tumors (*n*=53) | Treatment-naive primary tumors (*n*=919) |  |
|  | No. tumors engrafted | No. PDX established | Take rate | No.° tumors engrafted | No. PDX established | Take rate | *p* value |
| ER+ | 26 | 6 | 23% | 757 | 49 | 6% | *p*=0.007 |
| HER2+ | 9 | 2 | 22% | 34 | 9 | 26% | ns |
| TNBC | 18 | 14 | 78% | 128 | 44 | 34% | *p*=0.0006 |
| ALL | 53 | 22 | 42% | 919 | 102 | 11% | *p*<0.0001 |

**Supplementary Table 1**